Table 3 Subsequent treatment after first-generation epidermal growth factor receptor-tyrosine kinase inhibitor resistance
Group | Total (cases) | Continuation of TKI [cases (%)] | AZD9291 [cases (%)] | Chemo ± RT [cases (%)] | TKI plus chemo/RT [cases (%)] | BSC [cases (%)] |
|---|---|---|---|---|---|---|
CF | ||||||
 T790M+ | 72 | 23 (31.9) | 28 (38.9) | 10 (13.9) | 4 (5.6) | 7 (9.7) |
 T790M− | 103 | 41 (39.8) | 23 (22.3) | 21 (20.4) | 9 (8.7) | 9 (8.7) |
 Total | 175 | 64 (36.6) | 51 (29.1) | 31 (17.7) | 13 (7.4) | 16 (9.1) |
BF | ||||||
 T790M+ | 6 | 1 (16.7) | 1 (16.7) | 0 (0) | 0 (0) | 4 (66.7) |
 T790M− | 21 | 9 (42.9) | 3 (14.3) | 2 (9.5) | 2 (9.5) | 5 (23.8) |
 Total | 27 | 10 (37.0) | 4 (14.8) | 2 (7.4) | 2 (7.4) | 9 (33.3) |
OF | ||||||
 T790M+ | 53 | 10 (18.9) | 22 (41.5) | 11 (20.8) | 4 (7.5) | 6 (11.3) |
 T790M− | 23 | 7 (30.4) | 8 (34.8) | 3 (13) | 1 (4.3) | 4 (17.4) |
 Total | 76 | 17 (22.4) | 30 (39.5) | 14 (18.4) | 5 (6.6) | 10 (13.2) |